Not Yet Recruiting
Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma
NCT07385079
- Conditions
- Head and Neck Neoplasms, Nasopharyngeal Cancer, Nasopharyngeal Cancinoma (NPC), +9 more
- Locations
-
Not specified